Get started
Akebia Therapeutics, Inc.Akebia Therapeutics, Inc.Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

AKBA trade ideas

Random Pick of The Week | $AKBA BioTechWelcome to the first "Random Pick of The Week", where I will randomly select a ticker to chart based on comments posted below or sent via direct message. Want a technical breakdown? - Follow Me - Smash Like - Comment 1 Ticker Todays's Pick: AKBA / Akebia Therapeutics Inc. Looking at the great scheme of things, we can see that AKBA has been in a steady downtrend for the last 5 years with only a few points of high demand. We've seen some massive leaps throughout the last 5 years, which is as expected knowing that we are trading biotech. We look like we will sit in a wedge up toward the start of 2021, leaving us with sideways movement (-+8%) until. We look for a breakout and retest of this wedge if bulls have any hope of any run into the New Years'. If we break out, we have $3.95 set as a short-term target and $7 as our long-term. We must watch $2.75/$2.70 as our weekly support, if lost look to short toward $2.10/.20. FYI: Ignore the green box, it decided to change angles last second. DCJ | Happy Holidays
NASDAQ:AKBALong
by DotcomJack
$AKBA Akebia Therapeutics, attracting Dip Buyers Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
NASDAQ:AKBALong
by DEXWireNews
Not so easy moneyTrendline break, HUGE upside. Wait for the opening dump,even if it breaks the premarket peek at the open stay put waiting for that dump..then trade it from support to resistance entering above support and selling 20% below resistance. Tight Stoploss.. Daytrading Amplitude" At least 300 shares...The daily amplitude is way below ideal for day trading...this should be treated as a ONETIME BREAK ONLY for daytrading and wait for it to settle to swing trade it...Monitor daily for entry after the big break Good luck, Just a tought!
NASDAQ:AKBALong
by eltraderche
Breakout approaching In Akebia ThermaAkebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA. Akebia Therapeutics Inc. has given investors plenty of cause for concern, reflected by a share price that has dropped from $20 to $3 since Sept. '18. Sole commercial product Auryxia revenues were $80m in 2019 so far but sales affected by CMS withdrawing reimbursement for treatment of iron deficiency anemia (IDA). There are high hopes for commercial approval of Vadadustat; Akebia has milestone and revenue sharing agreements with a global network of commercial and development partners. Signs are encouraging; phase 3 clinical trial results due in early 2020. $100m non-dilutive loan secured should ensure the company can fund operations until 2021.
NASDAQ:AKBALong
by DEXWireNews